Market Data
Market Cap₹16,506 Cr.
52W High₹1,495.3
Current Price₹1,344.8
52W Low₹830
Down from 52W High10.1 %
Face Value₹2
Performance
ROCE23.78 %
ROE18.1 %
EPS (TTM)₹13.04
EPS Prev Qtr₹13.23
EPS Last Year₹10.6
EBITDA Qtr₹191.13 Cr.
Book Value₹272
Financial Health
Debt/Equity0.02
Debt/Profit0.09
Total Assets₹3,982.9 Cr.
Promoter Holding74.87 %
Earning Power19.03 %
Valuation
Stock P/E27.38
Industry P/E33.81
Price to Book4.95
Price to Sales6.37
Graham Number₹547.96
Key Metrics
Face Value
₹2
About Alivus Life Sciences Ltd
Healthcare · Pharmaceuticals
Alivus Life Sciences Ltd is listed on NSE in the Healthcare / Pharmaceuticals sector. Face value ₹2. Market cap ₹16,506 Cr.
Price Chart
Strengths & Weaknesses
Strengths
- The company has a strong ROCE of 28.61%, indicating efficient use of capital.
- It boasts a solid ROE of 21.4%, reflecting good return generation for shareholders.
- The company is debt-free with a Debt to Equity ratio of 0, reducing financial risk.
- The promoter holding stands at 74.87%, suggesting strong management control and alignment of interests.
Weaknesses
- The P/E ratio of 28.2 may indicate that the stock is overvalued relative to earnings.
- The P/B ratio of 6.03 suggests that the market values the company at a premium over its book value.
- The company does not currently offer a dividend yield, which might be a concern for income-focused investors.
Peer Comparison
| Name | CMP | P/E | Market Cap | Div Yield | NP Qtr | Qtr Profit Var% | Sales Qtr | Qtr Sales Var% | ROCE% | Debt/Eq |
|---|---|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | - | 36.51 | ₹4,41,477.63 Cr | 0.87% | ₹12,172.7 Cr | - | ₹59,910.52 Cr | - | 18.72% | 0.05 |
| Divis Laboratories Ltd | - | 86.48 | ₹2,53,031.38 Cr | 0.31% | ₹2,925 Cr | - | ₹11,230 Cr | - | 23.04% | 0 |
| Torrent Pharmaceuticals Ltd | - | 77.67 | ₹1,85,216.32 Cr | 0.78% | ₹2,156 Cr | - | ₹15,723 Cr | - | 15.1% | 1.76 |
| Zydus Lifesciences Ltd | - | 27.01 | ₹1,20,897.46 Cr | 0.08% | ₹4,492.2 Cr | - | ₹28,591.7 Cr | - | 16.76% | 0.43 |
| Cipla Ltd | - | 33.28 | ₹1,12,201.64 Cr | 0.94% | ₹3,364.84 Cr | - | ₹28,324.4 Cr | - | 13.24% | 0.01 |
| Laurus Labs Ltd | - | 99.31 | ₹1,08,698.22 Cr | 0.06% | ₹1,090.76 Cr | - | ₹7,269.64 Cr | - | 20.79% | 0.45 |
| Dr Reddys Laboratories Ltd | - | 31.6 | ₹1,02,039.12 Cr | 0.65% | ₹3,183.3 Cr | - | ₹33,227.9 Cr | - | 10.05% | 0.17 |
| Mankind Pharma Ltd | - | 49.29 | ₹1,00,752.43 Cr | 0.04% | ₹2,067.57 Cr | - | ₹14,737.88 Cr | - | 13.95% | 0.38 |
| Aurobindo Pharma Ltd | - | 26.56 | ₹97,814.24 Cr | 0.24% | ₹3,710.8 Cr | - | ₹34,935.29 Cr | - | 12.75% | 0.2 |
| Lupin Ltd | - | 16.64 | ₹94,274.49 Cr | 0.87% | ₹5,550.99 Cr | - | ₹29,966.58 Cr | - | 27.95% | 0.26 |
| Glenmark Pharmaceuticals Ltd | - | 36.67 | ₹65,922.11 Cr | 0.11% | ₹1,797.81 Cr | - | ₹17,736.56 Cr | - | 24.78% | 0.25 |
| Alkem Laboratories Ltd | - | 28.65 | ₹61,804.34 Cr | 1.03% | ₹2,206.3 Cr | - | ₹15,081.28 Cr | - | 19.75% | 0.12 |
| Biocon Ltd | - | 110.29 | ₹61,113.53 Cr | 0.13% | ₹416.4 Cr | - | ₹17,321.1 Cr | - | 2.87% | 0.43 |
| Abbott India Ltd | - | 35.22 | ₹56,860.69 Cr | 1.78% | ₹1,614.68 Cr | - | ₹7,004.38 Cr | - | 45.73% | 0 |
| Glaxosmithkline Pharmaceuticals Ltd | - | 46.73 | ₹49,091.33 Cr | 1.97% | ₹1,068.15 Cr | - | ₹3,954.94 Cr | - | 64.07% | 0 |
| Ipca Laboratories Ltd | - | 36.13 | ₹48,712.48 Cr | 0.31% | ₹1,379.76 Cr | - | ₹10,125.58 Cr | - | 21.48% | 0.09 |
| Anthem Biosciences Ltd | - | 83.03 | ₹47,949.68 Cr | 0.23% | ₹575.95 Cr | - | ₹2,002.34 Cr | - | 25.5% | 0.02 |
| Gland Pharma Ltd | - | 42.26 | ₹47,764.08 Cr | 0.69% | ₹1,128.8 Cr | - | ₹6,725.3 Cr | - | 15.21% | 0.02 |
| Ajanta Pharma Ltd | - | 38.87 | ₹44,109.77 Cr | 0.79% | ₹1,134.88 Cr | - | ₹5,776.17 Cr | - | 31.81% | 0.05 |
| J B Chemicals & Pharmaceuticals Ltd | - | 53.3 | ₹38,730.77 Cr | 0.39% | ₹709.46 Cr | - | ₹4,147.79 Cr | - | 23.03% | 0 |
Quarterly Results
| Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|
| Sales | 587.98 | 672.89 | 689.12 | 640.41 |
| ↳ QoQ Growth | - | +14.4% | +2.4% | -7.1% |
| Expenses | 427.25 | 461.27 | 494.79 | 449.29 |
| Operating Profit | 160.74 | 211.62 | 194.33 | 191.13 |
| OPM % | 27.34% | 31.45% | 28.2% | 29.84% |
| Other Income | 14.72 | 13.93 | 22.78 | 22.4 |
| Interest | 1.32 | 1.49 | 1.31 | 1.31 |
| Depreciation | 18.44 | 19.66 | 20.2 | 20.59 |
| EBITDA | 179.18 | 231.28 | 214.53 | 211.72 |
| EBITDA Margin % | 30.47% | 34.37% | 31.13% | 33.06% |
| Profit Before Tax | 174.14 | 198.39 | 215.8 | 212.22 |
| Tax % | 25.33% | 24.26% | 24.62% | 24.57% |
| Net Profit | 130.03 | 150.26 | 162.66 | 160.08 |
| ↳ QoQ Growth | - | +15.6% | +8.3% | -1.6% |
| EPS | 10.6 | 12.25 | 13.23 | 13.04 |
Balance Sheet
| Mar 2025 | Mar 2026 | |
|---|---|---|
| Equity Capital | 24.507 | 24.55 |
| Reserves | 2792.865 | 3307.59 |
| Borrowings | 0 | 56.77 |
| Other Liabilities | 594.08 | 593.99 |
| Total Liabilities | 3411.453 | 3982.9 |
| Fixed Assets | 962.607 | 1017.97 |
| CWIP | 94.252 | 273.4 |
| Investments | 477.69 | 780.46 |
| Other Assets | 1876.9 | 1911.07 |
| Total Assets | 3411.453 | 3982.9 |
Cash Flows
| Mar 2026 | |
|---|---|
| Cash from Operating Activity | 565.413 |
| Cash from Investing Activity | -570.153 |
| Cash from Financing Activity | -64.34 |
| Net Cash Flow | -69.08 |
Shareholding Pattern
| Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|
| Promoters % | 74.91% | 74.91% | 74.87% | 74.87% |
| FIIs % | 6.84% | 5.09% | 5.29% | 5.54% |
| DIIs % | 5.47% | 7.12% | 7.27% | 7.18% |
| Public % | 10.14% | 10.21% | 9.87% | 10.05% |
| No. of Shareholders | 1,35,643 | 1,32,748 | 1,27,969 | 1,25,559 |
Major Shareholders (>1%)
- Nirma LimitedPromoter and Promoter Group74.87%
- Quant Mutual Fund - Quant Small Cap FundPublic Shareholding2.51%
- Government Pension Fund GlobalPublic Shareholding2.40%
- Massachusetts Institute Of TechnologyPublic Shareholding1.23%
As of 2026-06-30View all shareholders →